Exicure Q2 net loss widens, exploring strategic alternatives

Reuters

08/09

Exicure <a href="https://laohu8.com/S/QTWO">Q2</a> net loss widens, exploring strategic alternatives

Overview

Exicure Q2 net loss widens to $2.6 mln from $0.6 mln yr ago
Company's cash position declines to $7.9 mln from $12.5 mln end of 2024
Exicure needs substantial financing to continue operations, per management

Outlook

Company needs substantial financing to continue operations
Exicure exploring strategic alternatives
Exicure uncertain about obtaining additional financing

Result Drivers

ACQUISITION IMPACT - Increased R&D and G&A expenses due to acquisition of GPCR Therapeutics USA Inc.
CASH DECLINE - Cash position fell to $7.9 mln from $12.5 mln at end of 2024
FINANCIAL NEEDS - Management states substantial financing needed to continue operations

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Net Income Before Tax		-$2.62 mln
Q2 Net Income		-$2.62 mln
Q2 Operating Expenses		$2.51 mln
Q2 Operating Income		-$2.51 mln

Press Release: ID:nBwbwQ1MGa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2558574789"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558574789\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558574789?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-09 04:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558574789","market":"fut","top_or_hot":-1,"title":"Exicure Q2 net loss widens, exploring strategic alternatives","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Exicure <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens, exploring strategic alternatives</title></head><body><p><span>Overview</span></p><ul><li><p>Exicure Q2 net loss widens to $2.6 mln from $0.6 mln yr ago</p></li><li><p>Company's cash position declines to $7.9 mln from $12.5 mln end of 2024</p></li><li><p>Exicure needs substantial financing to continue operations, per management</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company needs substantial financing to continue operations</p></li><li><p>Exicure exploring strategic alternatives</p></li><li><p>Exicure uncertain about obtaining additional financing</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ACQUISITION IMPACT - Increased R&amp;D and G&amp;A expenses due to acquisition of GPCR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> USA Inc.</p></li><li><p>CASH DECLINE - Cash position fell to $7.9 mln from $12.5 mln at end of 2024</p></li><li><p>FINANCIAL NEEDS - Management states substantial financing needed to continue operations</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income Before Tax</p></td><td></td><td><p>-$2.62 mln</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$2.62 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$2.51 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Income</p></td><td></td><td><p>-$2.51 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBwbwQ1MGa</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exicure Q2 net loss widens, exploring strategic alternatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExicure Q2 net loss widens, exploring strategic alternatives\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-09 04:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Exicure <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens, exploring strategic alternatives</title></head><body><p><span>Overview</span></p><ul><li><p>Exicure Q2 net loss widens to $2.6 mln from $0.6 mln yr ago</p></li><li><p>Company's cash position declines to $7.9 mln from $12.5 mln end of 2024</p></li><li><p>Exicure needs substantial financing to continue operations, per management</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company needs substantial financing to continue operations</p></li><li><p>Exicure exploring strategic alternatives</p></li><li><p>Exicure uncertain about obtaining additional financing</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ACQUISITION IMPACT - Increased R&amp;D and G&amp;A expenses due to acquisition of GPCR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> USA Inc.</p></li><li><p>CASH DECLINE - Cash position fell to $7.9 mln from $12.5 mln at end of 2024</p></li><li><p>FINANCIAL NEEDS - Management states substantial financing needed to continue operations</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income Before Tax</p></td><td></td><td><p>-$2.62 mln</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$2.62 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$2.51 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Income</p></td><td></td><td><p>-$2.51 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBwbwQ1MGa</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XCUR","symbol_name":"Exicure, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nPLX503A5B:1","article_id":"2558574789","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558574789","pubTimestamp":1754683905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Exicure Q2 net loss widens, exploring strategic alternativesOverviewExicure Q2 net loss widens to $2.6 mln from $0.6 mln yr agoCompany's cash position declines to $7.9 mln from $12.5 mln end of 2024Ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XCUR":"Exicure, Inc.","BK4139":"生物科技"},"translate_title":"Exicure第二季度净亏损扩大，探索战略替代方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XCUR":0.9},"content_text":"Exicure Q2 net loss widens, exploring strategic alternativesOverviewExicure Q2 net loss widens to $2.6 mln from $0.6 mln yr agoCompany's cash position declines to $7.9 mln from $12.5 mln end of 2024Exicure needs substantial financing to continue operations, per managementOutlookCompany needs substantial financing to continue operationsExicure exploring strategic alternativesExicure uncertain about obtaining additional financingResult DriversACQUISITION IMPACT - Increased R&D and G&A expenses due to acquisition of GPCR Therapeutics USA Inc.CASH DECLINE - Cash position fell to $7.9 mln from $12.5 mln at end of 2024FINANCIAL NEEDS - Management states substantial financing needed to continue operationsKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Net Income Before Tax-$2.62 mlnQ2 Net Income-$2.62 mlnQ2 Operating Expenses$2.51 mlnQ2 Operating Income-$2.51 mlnPress Release: ID:nBwbwQ1MGa(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}